GenomeDx's Decipher Test and Tissue-based Genomics Platform to be Featured in Nine Presentations at the American Urological Association Annual Meeting
Presentations to Include Data from Bladder Cancer Application of Decipher
SAN DIEGO, May 8, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that eight abstracts featuring the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer, will be presented at the American Urological Association Annual Meeting in New Orleans. In addition, a separate podium presentation will highlight new study results of the Decipher platform's application in bladder cancer.
Friday, May 15, 2015
Prostate Cancer: Markers I 10:30 a.m. to 12:30 p.m. CDT, Room 220-221
Title: Validation of the Decipher® prostate cancer classifier in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise
Abstract Number: MP1-11
Title: Evaluation of genomic signatures in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise
Abstract Number: MP1-04
Title: Comparative analysis of African American and European American men using a prostate cancer genomic classifier
Abstract Number: MP1-12
Prostate Cancer: Markers II 1 p.m. to 3 p.m. CDT, Room 220-221
Title: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes
Abstract Number: MP6-09
Title: A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer
Abstract Number: MP6-03
Sunday, May 17, 2015
Prostate Cancer: Staging I 1 p.m. to 3 p.m. CDT, Room 211-213
Title: Clinical validation of the 2005 ISUP Gleason grading system in a case-cohort of intermediate and high risk men undergoing radical prostatectomy
Abstract Number: MP53-17
Monday, May 18, 2015
Prostate Cancer: Basic Research IV 8 a.m. to 10 a.m. CDT, Room 211-213
Title: SPINK1 defines a molecular subtype of prostate cancer men with more rapid progression from biochemical recurrence to death in an at-risk, natural history cohort
Abstract Number: MP61-11
Prostate Cancer: Basic Research V 10:30 a.m. to 12:30 p.m. CDT, Room 217-219
Title: Anatomic tumor location not racial background impacts ETS family transcription factor and SPINK1 expression in prostate cancer
Abstract Number: MP66-16
Bladder Cancer: Staging 10:30 a.m. to 12:30 p.m. CDT, Room 214
Title: Can bladder cancer gene expression signatures be used to predict Lymph node metastasis at the time of radical cystectomy
Abstract Number: PD41-08
About Decipher®
The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.
Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.
Learn more at: www.DecipherTest.com and follow Decipher on Twitter at @DecipherTest and on Facebook.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com and follow us on Twitter at @GenomeDx, Facebook, LinkedIn and YouTube.
Media Contact:
Ian Stone
Canale Communications
619-849-5388
[email protected]
SOURCE GenomeDx Biosciences
Share this article